One question I don't here much discussion about GVAX- since the trial is being compared to Taxotere instead of placebo (Provenge)...does GVAX need to show statistically better survival than Taxotere....or would a smaller benefit combined with the improved safety profile be sufficient?
Market Data 
Markets 
AI
